

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions of the claims presented in the application.

1-20. (Cancelled)

21. (New) A monoclonal that is the monoclonal antibody designated 1A10, 1C3, or 82E1, or a chimeric or humanized form of the antibodies designated 1A10, 1C3 or 82E1.

22. (New) The monoclonal antibody of claim 21 that is the monoclonal antibody designated 1A10 or a chimeric or humanized form thereof.

23. (New) The monoclonal antibody of claim 22 that is the humanized form of the monoclonal antibody designated 1A10.

24. (New) The monoclonal antibody of claim 22 that is the monoclonal antibody designated 1A10.

25. (New) A pharmaceutical composition comprising the monoclonal antibody of claim 22 and one or more pharmaceutically acceptable carriers or additives.

26. (New) A method of treating a disease induced by accumulation of amyloid β comprising administering the monoclonal antibody of claim 22 to an individual in need of such treatment.

27. (New) The method of claim 26 wherein said disease is Alzheimer's disease.

28. (New) A method of inhibiting deposition of amyloid β comprising administering the monoclonal antibody of claim 22 to an individual in need of such inhibition.

29. (New) A method of treating Alzheimer's disease comprising administering the monoclonal antibody of claim 23 to an individual in need of such treatment.

30. (New) The monoclonal antibody of claim 21 that is the monoclonal antibody designated 1C3 or a chimeric or humanized form thereof.

31. (New) The monoclonal antibody of claim 30 that is the humanized form of the monoclonal antibody designated 1A10.

32. (New) The monoclonal antibody of claim 30 that is the monoclonal antibody designated 1C3.

33. (New) A pharmaceutical composition comprising the monoclonal antibody of claim 30 and one or more pharmaceutically acceptable carriers or additives.

34. (New) A method of treating a disease induced by accumulation of amyloid β comprising administering the monoclonal antibody of claim 30 to an individual in need of such treatment.

35. (New) The method of claim 34 wherein said disease is Alzheimer's disease.

36. (New) A method of inhibiting deposition of amyloid β comprising administering the monoclonal antibody of claim 30 to an individual in need of such inhibition.

37. (New) A method of treating Alzheimer's disease comprising administering the monoclonal antibody of claim 31 to an individual in need of such treatment.

38. (New) The monoclonal antibody of claim 21 that is the monoclonal antibody designated 82E1 or a chimeric or humanized form thereof.

39. (New) The monoclonal antibody of claim 38 that is the humanized form of the monoclonal antibody designated 1A10.

40. (New) The monoclonal antibody of claim 38 that is the monoclonal antibody designated 1C3.

41. (New) A pharmaceutical composition comprising the monoclonal antibody of claim 38 and one or more pharmaceutically acceptable carriers or additives.

42. (New) A method of treating a disease induced by accumulation of amyloid β comprising administering the monoclonal antibody of claim 38 to an individual in need of such treatment.

43. (New) The method of claim 42 wherein said disease is Alzheimer's disease.

44. (New) A method of inhibiting deposition of amyloid β comprising administering the monoclonal antibody of claim 38 to an individual in need of such inhibition.

45. (New) A method of treating Alzheimer's disease comprising administering the monoclonal antibody of claim 39 to an individual in need of such treatment.